1. Home
  2. OFS vs ELTX Comparison

OFS vs ELTX Comparison

Compare OFS & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OFS
  • ELTX
  • Stock Information
  • Founded
  • OFS 2001
  • ELTX 2011
  • Country
  • OFS United States
  • ELTX United States
  • Employees
  • OFS N/A
  • ELTX N/A
  • Industry
  • OFS Finance/Investors Services
  • ELTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • OFS Finance
  • ELTX Health Care
  • Exchange
  • OFS Nasdaq
  • ELTX Nasdaq
  • Market Cap
  • OFS 117.0M
  • ELTX 121.7M
  • IPO Year
  • OFS 2012
  • ELTX N/A
  • Fundamental
  • Price
  • OFS $8.82
  • ELTX $11.35
  • Analyst Decision
  • OFS
  • ELTX Strong Buy
  • Analyst Count
  • OFS 0
  • ELTX 2
  • Target Price
  • OFS N/A
  • ELTX $11.00
  • AVG Volume (30 Days)
  • OFS 34.2K
  • ELTX 99.0K
  • Earning Date
  • OFS 10-30-2025
  • ELTX 11-12-2025
  • Dividend Yield
  • OFS 15.40%
  • ELTX N/A
  • EPS Growth
  • OFS N/A
  • ELTX N/A
  • EPS
  • OFS 0.76
  • ELTX N/A
  • Revenue
  • OFS $43,337,000.00
  • ELTX N/A
  • Revenue This Year
  • OFS N/A
  • ELTX N/A
  • Revenue Next Year
  • OFS N/A
  • ELTX N/A
  • P/E Ratio
  • OFS $11.55
  • ELTX N/A
  • Revenue Growth
  • OFS N/A
  • ELTX N/A
  • 52 Week Low
  • OFS $7.81
  • ELTX $4.05
  • 52 Week High
  • OFS $9.80
  • ELTX $12.42
  • Technical
  • Relative Strength Index (RSI)
  • OFS 52.60
  • ELTX 55.62
  • Support Level
  • OFS N/A
  • ELTX $10.00
  • Resistance Level
  • OFS $8.79
  • ELTX $11.89
  • Average True Range (ATR)
  • OFS 0.10
  • ELTX 0.65
  • MACD
  • OFS -0.29
  • ELTX -0.07
  • Stochastic Oscillator
  • OFS 99.55
  • ELTX 71.43

About OFS OFS Capital Corporation

OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.

Share on Social Networks: